Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology -February 21, 2024 at 09:03 am EST
Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety...